LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk
LifeMD (NASDAQ:LFMD) has expanded its collaboration with Novo Nordisk to offer Ozempic® at $499 per month to eligible self-pay patients through its virtual care platform. The offering targets uninsured patients and those whose insurance doesn't cover GLP-1 therapies.
Through integration with NovoCare® Pharmacy, patients can access all FDA-approved dose strengths of Ozempic® and Wegovy® within LifeMD's comprehensive care platform, which includes virtual consultations, clinical support, diagnostic testing, and pharmacy coordination. The platform also provides access to Lilly's Zepbound® through integration with LillyDirect pharmacy provider.
Ozempic® is FDA-approved for type 2 diabetes, which affects approximately 36 million Americans. This collaboration aims to improve accessibility to authentic, FDA-approved GLP-1 treatments at competitive self-pay prices.
LifeMD (NASDAQ:LFMD) ha esteso la sua collaborazione con Novo Nordisk per offrire Ozempic® a 499$ al mese ai pazienti autonomi eleggibili tramite la sua piattaforma di assistenza virtuale. L'offerta è rivolta a chi non è assicurato o a chi la copertura assicurativa non comprende le terapie GLP-1.
Grazie all'integrazione con NovoCare® Pharmacy, i pazienti possono accedere a tutte le dosi approvate dalla FDA di Ozempic® e Wegovy® all'interno della piattaforma di cura completa di LifeMD, che include consultazioni virtuali, supporto clinico, test diagnostici e coordinazione farmaceutica. La piattaforma consente inoltre l'accesso a Zepbound® di Lilly tramite integrazione con il fornitore di farmacia LillyDirect.
Ozempic® è approvato dalla FDA per il diabete di tipo 2, che colpisce circa 36 milioni di americani. Questa collaborazione punta a migliorare l'accessibilità a trattamenti GLP-1 autentici e approvati dalla FDA a prezzi self-pay competitivi.
LifeMD (NASDAQ:LFMD) ha ampliado su colaboración con Novo Nordisk para ofrecer Ozempic® a 499 USD al mes a pacientes que pagan de su propio bolsillo elegibles a través de su plataforma de atención virtual. La oferta está dirigida a personas sin seguro y a aquellas cuyo seguro no cubre terapias GLP-1.
A través de la integración con NovoCare® Pharmacy, los pacientes pueden acceder a todas las dosis aprobadas por la FDA de Ozempic® y Wegovy® dentro de la plataforma integral de LifeMD, que incluye consultas virtuales, apoyo clínico, pruebas diagnósticas y coordinación farmacéutica. La plataforma también facilita el acceso a Zepbound® de Lilly mediante la integración con el proveedor de farmacia LillyDirect.
Ozempic® está aprobado por la FDA para la diabetes tipo 2, que afecta a aproximadamente 36 millones de estadounidenses. Esta colaboración busca mejorar la accesibilidad a tratamientos GLP-1 auténticos y aprobados por la FDA a precios de pago propio competitivos.
LifeMD (나스닥:LFMD)가 Novo Nordisk와의 협력을 확대하여 자가 비용으로 Eligible 환자들에게 Ozempic®를 월 499달러로 제공하는 플랫폼을 제공했습니다. 이 제안은 보험이 없거나 GLP-1 치료를 보험이 보장하지 않는 환자를 대상으로 합니다.
NovoCare® Pharmacy와의 통합을 통해 환자들은 LifeMD의 포괄적 진료 플랫폼 안에서 Ozempic® 와 Wegovy®의 FDA 승인 모든 용량으로 접근할 수 있으며, 가상 상담, 임상 지원, 진단 검사 및 약국 조정을 포함합니다. 또한 LillyDirect 약국 제공자와의 통합을 통해 Zepbound®에도 접근할 수 있습니다.
Ozempic®은 제2형 당뇨병에 대해 FDA 승인을 받았으며, 이는 약 3600만 명의 미국인에게 영향을 미칩니다. 이 협력은 FDA 승인 GLP-1 치료제를 합리적 자가부담 가격으로 더 쉽게 이용할 수 있도록 하는 것을 목표로 합니다.
LifeMD (NASDAQ:LFMD) a élargi sa collaboration avec Novo Nordisk pour proposer Ozempic® à 499 $ par mois aux patients éligibles en auto-paiement via sa plateforme de soins virtuels. Cette offre cible les patients sans assurance et ceux dont l’assurance ne couvre pas les thérapies GLP-1.
Grâce à l’intégration avec NovoCare® Pharmacy, les patients peuvent accéder à toutes les doses approuvées par la FDA d’Ozempic® et Wegovy® au sein de la plateforme de soins globale de LifeMD, qui comprend des consultations virtuelles, un support clinique, des tests diagnostiques et la coordination pharmaceutique. La plateforme donne également accès à Zepbound® de Lilly via l’intégration avec le fournisseur de pharmacie LillyDirect.
Ozempic® est approuvé par la FDA pour le diabète de type 2, qui touche environ 36 millions d’Américains. Cette collaboration vise à améliorer l’accès à des traitements GLP-1 authentiques et approuvés par la FDA à des prix de paiement personnel compétitifs.
LifeMD (NASDAQ:LFMD) hat seine Zusammenarbeit mit Novo Nordisk ausgeweitet, um Ozempic® für 499 $ pro Monat an berechtigte Selbstzahler über seine virtuelle Gesundheitsplattform anzubieten. Das Angebot richtet sich an Versicherungslose und an diejenigen, deren Versicherung GLP-1-Therapien nicht abdeckt.
Durch die Integration mit NovoCare® Pharmacy können Patienten alle FDA-genehmigten Dosierungsstärken von Ozempic® und Wegovy® innerhalb von LifeMDs umfassender Behandlungsplattform nutzen, die virtuelle Konsultationen, klinische Unterstützung, diagnostische Tests und Koordination der Apotheke umfasst. Die Plattform ermöglicht außerdem den Zugriff auf Zepbound® von Lilly durch die Integration mit dem LillyDirect-Apothekendienst.
Ozempic® ist von der FDA für Typ-2-Diabetes zugelassen, der etwa 36 Millionen Amerikaner betrifft. Diese Zusammenarbeit zielt darauf ab, den Zugang zu authentischen FDA-zugelassenen GLP-1-Behandlungen zu wettbewerbsfähigen Selbstzahlerpreisen zu verbessern.
LifeMD (المدرجة في ناسداك: LFMD) وسّعت تعاونها مع Novo Nordisk لتقديم Ozempic® بسعر 499 دولار شهرياً للمرضى الذين يدفعون بأنفسهم والمؤهلين من خلال منصتها للرعاية الافتراضية. تستهدف العروض المرضى غير المؤمن عليهم وأولئك الذين لا تغطيهم تأمين GLP-1.
من خلال التكامل مع NovoCare® Pharmacy، يمكن للمرضى الوصول إلى جميع تراكيب الجرعات المعتمدة من FDA لـ Ozempic® و Wegovy® ضمن منصة الرعاية الشاملة لدى LifeMD، والتي تشمل استشارات افتراضية، دعم سريري، فحوص تشخيصية، وتنسيق صيدلوي. كما تتيح المنصة الوصول إلى Zepbound® من Lilly من خلال التكامل مع موفر صيدلية LillyDirect.
Ozempic® معتمد من FDA للاستخدام في داء السكري من النوع 2، الذي يؤثر على نحو 36 مليون أمريكي. تهدف هذه الشراكة إلى تحسين الوصول إلى علاجات GLP-1 المعتمدة من FDA وبأسعار خارجية مريحة للشراء الذاتي.
LifeMD（纳斯达克股票代码：LFMD） 已扩大与诺和诺德的合作，向符合条件的自付患者通过其虚拟护理平台提供 Ozempic® 月费 499 美元。该计划面向无保险或保险不覆盖 GLP-1 疗法的患者。
通过与 NovoCare® Pharmacy 的整合，患者可以在 LifeMD 的综合护理平台内获取 Ozempic® 和 Wegovy® 的所有 FDA 批准剂量级别，平台包括 虚拟咨询、临床支持、诊断检测和药房协作。该平台还通过与 LillyDirect 药房提供商的整合，提供 Lilly 的 Zepbound® 的访问。
Ozempic® 已获 FDA 批准用于2型糖尿病，约有 3600 万美国人受到影响。这一合作旨在以具有竞争力的自付价格提高对正品、FDA 批准的 GLP-1 治疗方案的可及性。
- Competitive pricing of Ozempic® at $499 per month for self-pay patients
- Integration with major pharmaceutical companies (Novo Nordisk and Lilly) expanding drug access
- Comprehensive end-to-end virtual care platform offering multiple services
- Access to large market with 36 million Americans affected by type 2 diabetes
- Limited to self-pay patients and those without insurance coverage for GLP-1 therapies
Insights
LifeMD's $499 Ozempic offering enhances revenue potential and strengthens market position in the competitive GLP-1 telehealth space.
LifeMD's expanded collaboration with Novo Nordisk to offer Ozempic® at $499 per month to self-pay patients represents a strategic enhancement of their GLP-1 medication portfolio. This builds on their existing Wegovy® offering, creating a more comprehensive diabetes and weight management solution through their telehealth platform.
The pricing is particularly noteworthy in the competitive GLP-1 market. At
For LifeMD, this represents significant revenue potential. The company can leverage its existing telehealth infrastructure while expanding its addressable market to include both weight management and diabetes patients. The integration with NovoCare® Pharmacy creates a seamless end-to-end patient experience that differentiates LifeMD from competitors who may offer consultations but struggle with reliable medication fulfillment.
LifeMD's multi-partner strategy, which now includes collaborations with both Novo Nordisk for Ozempic®/Wegovy® and Lilly for Zepbound®, positions the company advantageously in the telehealth GLP-1 space. By securing direct manufacturer relationships, LifeMD addresses authenticity concerns while potentially improving their margins compared to telehealth providers who must source medications through third-party pharmacies.
This development reinforces LifeMD's business model of combining virtual consultations with medication access, potentially increasing both patient acquisition and retention metrics as they offer solutions for chronic conditions requiring ongoing care.
Ozempic® is now available at this reduced price to eligible self-pay LifeMD patients
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an additional offering through its collaboration with Novo Nordisk that provides access to Ozempic® (semaglutide), a GLP-1 RA for patients with type 2 diabetes, at
LifeMD’s telehealth platform is seamlessly integrated with NovoCare® Pharmacy to provide easy, reliable access to Novo Nordisk’s FDA-approved GLP-1 medications, Ozempic® and Wegovy®, at the most competitive cash-pay price. Patients benefit from a comprehensive care journey that includes:
- Virtual consultations with LifeMD’s 50-state affiliated medical group,
- Ongoing clinical support from licensed providers,
- Access to nationwide diagnostic testing,
- Pharmacy coordination with fast, reliable shipping and real-time order tracking, and
- Simplified billing and payment options.
“Our expanded collaboration with Novo Nordisk further advances LifeMD’s mission to make high-quality, branded medications more affordable and accessible for millions of Americans,” said Justin Schreiber, Chairman and CEO of LifeMD. “By broadening the program to now include Ozempic®, in addition to Wegovy®, we’re strengthening our ability to deliver FDA-approved GLP-1 therapies at the most competitive self-pay prices on the market—within a seamless, clinically supported patient experience from prescription to fulfillment. Novo Nordisk’s continued commitment to improving patient access allows LifeMD’s platform to play an important role in supporting better outcomes for millions of Americans.”
Ozempic® is the GLP-1 with the broadest range of FDA-approved indications for adults with type 2 diabetes, a chronic disease affecting approximately 36 million Americans. Today, millions of people have taken Ozempic® in the U.S. to help address these chronic conditions, yet there are still some without adequate coverage seeking improved access.
“Through established platforms like LifeMD, we are reaching patients directly where they seek care, offering proven therapies to those who may not have coverage today,” said Dave Moore, Executive Vice President, U.S. Operations of Novo Nordisk Inc. “The addition of Ozempic® to the LifeMD platform is another step in our mission to improve access for these patients to our authentic, FDA-approved treatments as they seek affordable options to help manage serious chronic conditions like type 2 diabetes.”
Direct manufacturer collaborations strengthen LifeMD’s ability to expand access to authentic, FDA-approved therapies. As part of its multi-partner strategy, LifeMD’s telehealth platform is also integrated with LillyDirect pharmacy provider, Gifthealth, to offer streamlined access of single-dose vials of Lilly’s prescription obesity treatment Zepbound® (tirzepatide) to eligible LifeMD patients. These self-pay, branded therapeutic options complement LifeMD’s insurance-sponsored pharmacy programs, as well as other non-GLP-1 prescriptions for those seeking even more affordable therapies.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact:
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact:
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com
FAQ
How much does Ozempic cost through LifeMD's platform?
What services does LifeMD (LFMD) provide with its Ozempic program?
Who is eligible for LifeMD's $499 Ozempic program?
What other GLP-1 medications does LifeMD offer besides Ozempic?
How does LifeMD's partnership with Novo Nordisk work?
